Company news
Beam Therapeutics Inc. news in 2022
Beam Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
December 9, 2022
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
December 1, 2022
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
December 1, 2022
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
November 29, 2022
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
November 13, 2022
Beam Therapeutics to Participate in Upcoming Investor Conferences
November 8, 2022
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 6, 2022
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
November 2, 2022
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection
September 18, 2022
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
August 31, 2022
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
August 8, 2022
Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 1, 2022
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
July 31, 2022
Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant
June 26, 2022
Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
June 2, 2022
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
May 8, 2022
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting
May 1, 2022
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
March 24, 2022
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
March 7, 2022
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
February 27, 2022
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 8, 2022
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 9, 2022
Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones
January 8, 2022
Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Decks in 2022
- Corporate Update (January 2022)
Corporate update · 26 slides · Jan 10, 2022